1. Home
  2. SLN vs ANTA Comparison

SLN vs ANTA Comparison

Compare SLN & ANTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • ANTA
  • Stock Information
  • Founded
  • SLN 1994
  • ANTA 2022
  • Country
  • SLN United Kingdom
  • ANTA Singapore
  • Employees
  • SLN N/A
  • ANTA N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • ANTA Investment Bankers/Brokers/Service
  • Sector
  • SLN Health Care
  • ANTA Finance
  • Exchange
  • SLN Nasdaq
  • ANTA Nasdaq
  • Market Cap
  • SLN 268.8M
  • ANTA 294.7M
  • IPO Year
  • SLN N/A
  • ANTA 2025
  • Fundamental
  • Price
  • SLN $4.73
  • ANTA $11.75
  • Analyst Decision
  • SLN Buy
  • ANTA Strong Buy
  • Analyst Count
  • SLN 5
  • ANTA 2
  • Target Price
  • SLN $32.60
  • ANTA $19.25
  • AVG Volume (30 Days)
  • SLN 50.2K
  • ANTA 20.4K
  • Earning Date
  • SLN 11-13-2025
  • ANTA 08-12-2025
  • Dividend Yield
  • SLN N/A
  • ANTA N/A
  • EPS Growth
  • SLN N/A
  • ANTA N/A
  • EPS
  • SLN N/A
  • ANTA 0.24
  • Revenue
  • SLN $27,169,000.00
  • ANTA $56,997,910.00
  • Revenue This Year
  • SLN N/A
  • ANTA $65.94
  • Revenue Next Year
  • SLN N/A
  • ANTA $59.39
  • P/E Ratio
  • SLN N/A
  • ANTA $48.43
  • Revenue Growth
  • SLN 22.28
  • ANTA 405.62
  • 52 Week Low
  • SLN $1.97
  • ANTA $10.19
  • 52 Week High
  • SLN $20.48
  • ANTA $27.72
  • Technical
  • Relative Strength Index (RSI)
  • SLN 41.23
  • ANTA N/A
  • Support Level
  • SLN $4.77
  • ANTA N/A
  • Resistance Level
  • SLN $5.80
  • ANTA N/A
  • Average True Range (ATR)
  • SLN 0.36
  • ANTA 0.00
  • MACD
  • SLN -0.03
  • ANTA 0.00
  • Stochastic Oscillator
  • SLN 22.46
  • ANTA 0.00

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About ANTA Antalpha Platform Holding Company Ordinary Shares

Antalpha Platform Holding Co provides financing, technology and risk management solutions to the digital asset industry. It is a provider of supply chain financing solutions to institutional and corporate participants in the Bitcoin mining industry, offering loans secured by Bitcoin and Bitcoin mining machines. It has developed a technology platform, Antalpha Prime, which enables customers to apply for and manage their digital asset loans while allowing to closely monitor collateral positions.

Share on Social Networks: